000739 Apeloa Pharmaceutical
- 16.27
- -0.37-2.22%
Apeloa Pharmaceutical News
Apeloa PharmaceuticalLtd (SZSE:000739) Investors Are Sitting on a Loss of 50% If They Invested Three Years Ago
Apeloa Pharmaceutical Gets Drug Registration for Influenza Treatment
Apeloa Pharmaceutical (000739.SZ): Kangyu Pharmaceutical has received the pharmaceutical registration certificate for oseltamivir phosphate capsules.
On December 9th, apeloa pharmaceutical (000739.SZ) announced that recently, its wholly-owned subsidiary Zhejiang Puluokangyu Pharmaceutical Co., Ltd. (referred to as "Kangyu Pharmaceutical") received the "Drug Registration Certificate" for oseltamivir phosphate capsules issued by the National Medical Products Administration. Oseltamivir phosphate capsules are used for the treatment of type A and type B influenza in adults and children aged 1 year and older. Patients should use it within 48 hours of the first appearance of symptoms; it is also used for the prevention of type A and type B influenza in adults and adolescents aged 13 years and older. According to relevant data, Oseltamivir phosphate capsules 2
Apeloa Pharmaceutical Signs Strategic Cooperation Framework Deal; Shares Up 3%
Apeloa Pharmaceutical (000739.SZ): signed a global strategy cooperation framework agreement with Jixing Hong Kong.
On November 28th, Gelonhui announced that Apeloa Pharmaceutical (000739.SZ) disclosed that the company ('Party B') and Jixing Pharmaceuticals Hong Kong Limited (referred to as 'Jixing Hong Kong' or 'Party A') recently signed a 'Strategic Cooperation Framework Agreement' based on the principles of equality, mutual benefit, and complementary advantages. The two parties have reached a consensus on the cooperative relationship of the CDMO project, formed a strategic partnership, and will carry out long-term cooperation on the CDMO project.
Apeloa Pharmaceutical Unit Gets China Approval for Bile Flow Injection
Apeloa Pharmaceutical (000739.SZ): Adenosine Diaminesulfonic Acid has obtained the approval notice for the application for listing of chemical raw materials.
On November 21, Gelunhui: Recently, Apeloa Pharmaceutical (000739.SZ) announced that its wholly-owned subsidiary Zhejiang Apeloa Jiayuan Pharmaceutical Co., Ltd. (hereinafter referred to as "Jiayuan Pharmaceutical") has received the "Chemical Raw Materials Pharmaceutical Market Application Approval Notification Letter" for Adenosine Phosphoric Acid issued by the National Medical Products Administration (hereinafter referred to as the "NMPA"). Adenosine phosphate is a natural physiologically active molecule that exists in all tissues and body fluids, with the highest content in the liver; adenosine phosphate has three major functions: methyl transfer, sulfonyl transfer, and propylamine transfer, participating in important biochemical reactions in the body, helping to prevent bile stasis.
gf sec: The upstream prices of penicillin and cephalosporins are fluctuating at a high level, while the active pharmaceutical ingredient is finding a bottom and stabilizing.
According to the data from the National Bureau of Statistics, in September 2024, the month-on-month PPI value of chemical drug active pharmaceutical ingredient manufacturing was 97.10, an increase of 2.0 compared to the previous month, and an increase of 1.63 from the average of 95.47 in the first half of 2024. Since the year 2023, when the month-on-month PPI of active pharmaceutical ingredient manufacturing fell below 100 for the whole year, the recent PPI value has been in an increasing state, indicating that the overall price of active pharmaceutical ingredients is in a phase of slight bottoming and recovery.
Apeloa Pharmaceutical Co.,Ltd's (SZSE:000739) Last Week's 5.2% Decline Must Have Disappointed Private Companies Who Have a Significant Stake
Apeloa Pharmaceutical (000739.SZ): Levofloxacin tablets approved to add 0.25g specification.
Gelonghui, November 18th | Apeloa Pharmaceutical (000739.SZ) announced that recently, Apeloa Pharmaceutical Co., Ltd., a holding subsidiary of Zhejiang Apeloa Kangyu Pharmaceutical Co., Ltd. (hereinafter referred to as "Kangyu Pharmaceutical"), received the National Medical Products Administration's issued Levofloxacin Tablets Supplementary Application Approval Notice, approved to increase the 0.25g specification. Levofloxacin tablets are the levorotatory optical isomer of ofloxacin, a third-generation quinolone antibiotic, with a broad spectrum and strong antibacterial properties; it is used to treat mild, moderate, and severe infections in adults (≥18 years old) caused by designated sensitive strains.
Apeloa Pharmaceutical Unit Gets Nod to Market Hepatitis Drug Ingredient
Apeloa Pharmaceutical (000739.SZ): Kangyu Pharmaceutical's meglumine pirepivir active pharmaceutical ingredient approved for marketing.
Geelonghui November 13 | Apeloa Pharmaceuticals (000739.SZ) announced that recently, Zhejiang Apeloa Pharmaceutical Co., Ltd., a wholly-owned subsidiary of Apeloa Pharmaceuticals Limited, received the approval notice for the listing application of sulfamethoxazole prelefuve "Chemical raw material pharmaceutical" issued by the National Medical Products Administration. Sulfamethoxazole prelefuve tablets (trade name: Xin Shumu) is a Class 1 new drug developed by Xi'an Xintong pharmaceutical Research Co., Ltd. (hereinafter referred to as "Xintong Pharmaceutical"), declared and produced by its wholly-owned subsidiary Xi'an Gelan Xintong Pharmaceutical Co., Ltd. (hereinafter referred to as "Gelan Xintong"), used for
Apeloa Pharmaceutical's Adenosylmethionine Butanedisulfonate Tablets Get Nod for Registration
Apeloa Pharmaceutical (000739.SZ): The holding subsidiary Dipyridamole Aspirin Enteric-coated Tablets obtained the pharmaceutical registration certificate.
Gelonghui November 11th | Apeloa Pharmaceutical (000739.SZ) announced that recently, its controlling subsidiary Zhejiang Apeloa Kangyu Pharmaceutical Co., Ltd. (hereinafter referred to as "Kangyu Pharmaceutical") has received the Drug Registration Certificate for Adenosine Disodium Taurocholate Enteric-coated Tablets issued by the National Medical Products Administration (referred to as "NMPA"). Adenosine Disodium Taurocholate Enteric-coated Tablets are suitable for pre-cirrhotic and cirrhotic intrahepatic cholestasis and intrahepatic cholestasis of pregnancy. S-Adenosylmethionine (SAMe) is a natural physiologically active molecule that exists in all tissues and body fluids of the human body, with the liver having the richest content; adenosine.
Apeloa Pharmaceutical Unit Gets China Supplementary Drug Nod for Antidepressant
Apeloa Pharmaceutical (000739.SZ): A subsidiary holding company, Hydrochloride Anfei Ketone Sustained-release Tablets (Ⅱ), has received a supplementary application approval notice.
As of November 5th, apeloa pharmaceutical (000739.SZ) announced that its holding subsidiary Zhejiang Puluo Kangyu Pharmaceutical Co., Ltd. (hereinafter referred to as 'Kangyu Pharmaceutical') recently received the National Medical Products Administration's issuance of the supplementary application approval notice for Hydrochloride Anfeniketon Sustained-Release Tablets (Ⅱ), approving the addition of the 150mg specification for this product, and issuing the drug approval number. The company already has the 300mg specification of this product on the market. With the newly approved 150mg specification, it can provide more options for the market promotion of this product, which is beneficial for expanding the domestic market of this product; at the same time, it also enriches
Apeloa PharmaceuticalLtd (SZSE:000739) Seems To Use Debt Quite Sensibly
Apeloa Pharmaceutical (000739.SZ): Currently, the company expects the renewal rules to be relatively mild, with overall price declines limited.
Galunhui October 21st|Apeloa Pharmaceutical (000739.SZ) stated at an investor relations event that currently, the formulation of centralized procurement accounts for about 45% of the formulation business. Centralized procurement is bullish for the company, so the company hopes to have more products participate in centralized procurement and leverage the enterprise advantage with manufacturing as its core. In the recent Jiangsu Alliance Procurement and Guangdong Alliance Procurement, some products will also participate. Some are for renewal, some are for the first time, with approximately 4-5 varieties. Currently, it is expected that the renewal rules will be relatively mild, and the overall price decrease will be limited.
Apeloa Pharmaceutical (000739.SZ): The existing business of the company already has medical beauty raw material related business exceeding 0.2 billion yuan.
Gelonghui October 21st│Apeloa Pharmaceutical (000739.SZ) stated at an investor relations event that the existing business already has medical beauty raw material related business exceeding 0.2 billion yuan, and in the future will continue to focus on the company's core competitiveness around technologies such as synthetic biology and enzyme catalysis platforms, as well as manufacturing capabilities like biological fermentation. In terms of the market, short-term focus will be on cosmetics raw materials, beauty products, collagen, etc., and there may be future layouts of more categories such as botulinum toxin. Currently, cooperation relationships have been established with some customer groups, and the company has also passed audits by internationally renowned cosmetic companies.
Apeloa Pharmaceutical (000739.SZ): Semaglutide is expected to obtain clinical approval by the end of this month or early next month.
Apeloa Pharmaceutical (000739.SZ) stated at an investor relations event on October 21 that in terms of production capacity, the peptide active pharmaceutical ingredient workshop plans to invest 0.3 billion yuan, with a design capacity of 0.012-0.02 million liters. Currently, the production capacity construction is in the design phase. In terms of the market, the company mainly focuses on pharmaceutical peptides and cosmetic peptides; among them, Simi Gelutide is expected to obtain clinical batch approval by the end of this month or early next month. Previous work has been completed, and currently the CDE has been accepted, with targets expected to complete relevant work before the patent expires.
No Data
